Usefulness of continuous porous hydroxyapatite ceramics with bone marrow stromal cells

1.连续多孔羟基磷灰石陶瓷（cp-HA）由称为骨置换材料的β-磷酸三钙（β-TCP）和作为亲热稳定相的α-磷酸三钙（α-TCP）组成，其特点是孔隙度约为85mm，孔径约为0.8mm。此外，我们尝试制作一种尽可能降低成骨细胞浸润范围内孔径以增加强度的cp-HA，但采用本研究所采用的cp-HA制作方法，将软烧聚氨酯形式浸在10%二氧化硅成分磷灰石悬浮液中，孔隙被表面张力堵塞，无法制造孔径小于0.8mm的cp-HA。因此实验采用孔径分别为1.0mm和0.8mm.2的cp-HA。在不同孔径（1.0mm和0.8mm）的实验中，骨化量和骨形成率没有差异。我们认为，在不同的孔直径水平上，成骨细胞对孔的侵入并没有什么不同。但大孔径的cp-HA易碎，不宜用于临床。此外，我们证实cpHA直接接触新骨，孔内无结缔组织，但cp-HA在体内不吸收，不被骨取代。为了使cp-HA包含BMSC，必须将纤维蛋白原与BMSC混合。在体内6个月和12个月，即中长期，cp-HA仅包含BMSC和cp-HA的情况下，新骨数量的差异未得到证实。然而，由于BMSC成分的影响可能会更早出现，因此短期的实验将需要在未来进行。

1.The continuous porous hydroxyapatite ceramics (cp-HA) consisted of β-tricalcium phosphate (β-TCP) known as bone displacement materials, and α-tricalcium phosphate (α-TCP) as a thermophile stable phase, and it's characteristics is that the porosity was about 85mm, and the pore diameter was about 0.8mm. Furthermore, we tried making of a cp-HA which lowered pore diameter by the range that osteoblast could infiltrate as much as possible to add to intensity, but pore was clogged up by surface tension of suspension to dip a soft firing polyurethane form to 10% silicon dioxide component apatite suspension by manufacture methods of the cp-HA which we used by this study, and the manufacture of lower than porous diameter 0.8mm cp-HA was impossible. Therefore the experiment was used cp-HA of pore diameter 1.0mm and 0.8mm.2.In a difference (1.0mm and 0.8mm) of the pore diameter used for the experiment, the difference was not found in ossiferous quantity and bone formation rate. It is thought that this is not different in an invasion of osteoblast to pores in a difference of porous diameter of this level. But a cp-HA whose pore diameter is massive becomes fragile, then it is not used for clinic. In addition, we confirmed that cpHA contacted new bone directly without connective tissue in pore, but cp-HA did not resorb in vivo and was not replaced by bone.3.In order to make cp-HA included BMSC, it was necessary to mix fibrinogen with BMSC. The difference of quantity of new bone was not confirmed in a condition of cp-HA included BMSC and cp-HA only in 6 months and 12 months, namely a middle long term, in vivo. However, it is though that the experiment in a short term will need in future because the effect of a BMSC component may appear earlier.